Intensification of medication and glycaemic control among patients with type 2 diabetes - the ADVANCE trial
- PMID: 24251579
- DOI: 10.1111/dom.12238
Intensification of medication and glycaemic control among patients with type 2 diabetes - the ADVANCE trial
Abstract
Aims: The aim of this study was to assess associations between patient characteristics, intensification of blood glucose-lowering treatment through oral glucose-lowering therapy and/or insulin and effective glycaemic control in type 2 diabetes.
Methods: 11 140 patients from the Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation (ADVANCE) trial who were randomized to intensive glucose control or standard glucose control and followed up for a median of 5 years were categorized into two groups: effective glycaemic control [haemoglobin A1c (HbA1c) ≤ 7.0% or a proportionate reduction in HbA1c over 10%] or ineffective glycaemic control (HbA1c > 7.0% and a proportionate reduction in HbA1c less than or equal to 10%). Therapeutic intensification was defined as addition of an oral glucose-lowering agent or commencement of insulin. Pooled logistic regression models examined the associations between patient factors, intensification and effective glycaemic control.
Results: A total of 7768 patients (69.7%), including 3198 in the standard treatment group achieved effective glycaemic control. Compared to patients with ineffective control, patients with effective glycaemic control had shorter duration of diabetes and lower HbA1c at baseline and at the time of treatment intensification. Treatment intensification with addition of an oral agent or commencement of insulin was associated with a 107% [odds ratio, OR: 2.07 (95% confidence interval, CI: 1.95-2.20)] and 152% [OR: 2.52 (95% CI: 2.30-2.77)] greater chance of achieving effective glycaemic control, respectively. These associations were robust after adjustment for several baseline characteristics and not modified by the number of oral medications taken at the time of treatment intensification.
Conclusions: Effective glycaemic control was associated with treatment intensification at lower HbA1c levels at all stages of the disease course and in both arms of the ADVANCE trial.
Keywords: HbA1c; glycaemic control; therapy; treatment intensification; type 2 diabetes.
© 2013 John Wiley & Sons Ltd.
Similar articles
-
Impact of delaying treatment intensification with a glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes uncontrolled on basal insulin: A longitudinal study of a US administrative claims database.Diabetes Obes Metab. 2018 Apr;20(4):831-839. doi: 10.1111/dom.13156. Epub 2017 Dec 4. Diabetes Obes Metab. 2018. PMID: 29119712 Free PMC article.
-
Durable change in glycaemic control following intensive management of type 2 diabetes in the ACCORD clinical trial.Diabetologia. 2014 Oct;57(10):2030-7. doi: 10.1007/s00125-014-3318-5. Epub 2014 Jul 2. Diabetologia. 2014. PMID: 24985147 Free PMC article. Clinical Trial.
-
Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trial.Diabetes Obes Metab. 2014 Oct;16(10):963-70. doi: 10.1111/dom.12303. Epub 2014 May 6. Diabetes Obes Metab. 2014. PMID: 24725616 Free PMC article. Clinical Trial.
-
A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo.Diabetes Obes Metab. 2013 Mar;15(3):213-23. doi: 10.1111/dom.12007. Epub 2012 Oct 3. Diabetes Obes Metab. 2013. PMID: 22958381 Review.
-
The economic and clinical benefits of adequate insulin initiation and intensification in people with type 2 diabetes mellitus.Diabetes Obes Metab. 2012 Jan;14(1):47-57. doi: 10.1111/j.1463-1326.2011.01487.x. Epub 2011 Nov 22. Diabetes Obes Metab. 2012. PMID: 21834876 Review.
Cited by
-
Evidence-Experience Gap and Future Perspective on the Treatment of Peripheral Artery Disease.J Atheroscler Thromb. 2021 Dec 1;28(12):1251-1259. doi: 10.5551/jat.RV17058. Epub 2021 Jun 2. J Atheroscler Thromb. 2021. PMID: 34078765 Free PMC article.
-
Associated risk factors in the early stage of diabetic retinopathy.Eye Vis (Lond). 2019 Aug 1;6:23. doi: 10.1186/s40662-019-0148-z. eCollection 2019. Eye Vis (Lond). 2019. PMID: 31388513 Free PMC article.
-
Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia.Eur J Vasc Endovasc Surg. 2019 Jul;58(1S):S1-S109.e33. doi: 10.1016/j.ejvs.2019.05.006. Epub 2019 Jun 8. Eur J Vasc Endovasc Surg. 2019. PMID: 31182334 Free PMC article.
-
Global vascular guidelines on the management of chronic limb-threatening ischemia.J Vasc Surg. 2019 Jun;69(6S):3S-125S.e40. doi: 10.1016/j.jvs.2019.02.016. Epub 2019 May 28. J Vasc Surg. 2019. PMID: 31159978 Free PMC article.
-
Factors Associated with Diabetes-Related Clinical Inertia in a Managed Care Population and Its Effect on Hemoglobin A1c Goal Attainment: A Claims-Based Analysis.J Manag Care Spec Pharm. 2019 Mar;25(3):304-313. doi: 10.18553/jmcp.2019.25.3.304. J Manag Care Spec Pharm. 2019. PMID: 30816810 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical